SPAC1A6.10 Antibody

What is SPAC1A6.10 and what cellular functions does it perform?

SPAC1A6.10 is a protein from Schizosaccharomyces pombe (fission yeast) that functions as a tRNA threonylcarbamoyladenosine dehydratase (EC 6.1.-.-), also known as t(6)A37 dehydratase . This enzyme is involved in the modification of tRNAs, specifically in the dehydration of threonylcarbamoyladenosine at position 37 of certain tRNAs. This post-transcriptional modification is crucial for proper tRNA function, codon recognition, and translational fidelity. The protein was initially classified as "uncharacterized," reflecting gaps in our understanding of its complete functional profile despite knowledge of its enzymatic activity.

What types of SPAC1A6.10 antibodies are available for research applications?

Based on available information, researchers can access polyclonal antibodies for SPAC1A6.10 detection. Specifically, rabbit polyclonal antibodies against Schizosaccharomyces pombe (strain 972/24843) SPAC1A6.10 are commercially available . These antibodies are purified using antigen-affinity techniques and have applications in ELISA and Western Blot analyses. Recombinant SPAC1A6.10 protein is also available with greater than 85% purity as determined by SDS-PAGE, which can be useful for antibody production or as positive controls in experiments .

How does the structure of SPAC1A6.10 relate to its function?

While comprehensive structural data for SPAC1A6.10 is not extensively documented in the provided search results, its function as a tRNA threonylcarbamoyladenosine dehydratase suggests it belongs to the family of enzymes that catalyze dehydration reactions. The protein likely contains conserved catalytic domains characteristic of dehydratases, including nucleotide-binding motifs for interaction with tRNA substrates. Understanding the structure-function relationship is critical for researchers designing experiments to probe specific domains or developing inhibitors for mechanistic studies. Further structural analysis using X-ray crystallography or cryo-EM would provide valuable insights into the catalytic mechanism.

What are the optimal conditions for using SPAC1A6.10 antibodies in Western blot applications?

For Western blot applications using rabbit anti-SPAC1A6.10 polyclonal antibodies, researchers should follow these methodological guidelines:

• Sample preparation: Extract total protein from S. pombe cells in mid-log phase using a buffer containing protease inhibitors to prevent degradation.

• Protein separation: Load 20-50 μg of total protein per lane on a 10-12% SDS-PAGE gel.

• Transfer conditions: Transfer proteins to a PVDF or nitrocellulose membrane at 100V for 1 hour in Tris-glycine buffer with 20% methanol.

• Blocking: Block the membrane with 5% non-fat dry milk in TBST (TBS with 0.1% Tween-20) for 1 hour at room temperature.

• Primary antibody incubation: Dilute the anti-SPAC1A6.10 antibody at 1:1000 to 1:2000 in blocking solution and incubate overnight at 4°C.

• Washing: Wash the membrane 3-4 times with TBST, 5-10 minutes each.

• Secondary antibody incubation: Incubate with HRP-conjugated anti-rabbit IgG (1:5000-1:10000) for 1 hour at room temperature.

• Detection: Develop using enhanced chemiluminescence (ECL) substrate.

These conditions may require optimization depending on the specific experiment and sample characteristics.

What are the recommended protocols for ELISA using SPAC1A6.10 antibodies?

For ELISA applications with SPAC1A6.10 antibodies, researchers should implement the following protocol based on standard antibody-based detection methodologies:

Direct ELISA Protocol:

• Coating: Coat 96-well microtiter plates with purified SPAC1A6.10 protein (1-5 μg/ml in carbonate-bicarbonate buffer, pH 9.6) overnight at 4°C.

• Blocking: Block with 1-3% BSA in PBS for 1-2 hours at room temperature.

• Primary antibody: Add serially diluted anti-SPAC1A6.10 antibody (starting from 1000 ng/ml down to 0.064 ng/ml) in blocking buffer, incubate for 2 hours at room temperature.

• Washing: Wash 4-5 times with PBS-T (PBS with 0.05% Tween-20).

• Secondary antibody: Add HRP-conjugated anti-rabbit IgG (1:10,000) in blocking buffer, incubate for 1 hour at room temperature.

• Washing: Repeat washing step.

• Detection: Add TMB substrate and incubate for 10 minutes in the dark, stop the reaction with 1M HCl, and read absorbance at 450 nm with reference at 620 nm .

This protocol is adapted from established ELISA methodologies demonstrated in similar antibody applications.

How can SPAC1A6.10 antibodies be validated for specificity in S. pombe research?

Validation of SPAC1A6.10 antibodies for specificity requires multiple complementary approaches:

Table 1: Antibody Validation Strategies for SPAC1A6.10 Research

Each validation approach provides complementary evidence for antibody specificity, and researchers should implement at least two methods to ensure reliable results.

What are common causes of non-specific binding when using SPAC1A6.10 antibodies, and how can they be mitigated?

Non-specific binding is a common challenge when working with polyclonal antibodies against yeast proteins. Several factors can contribute to this issue, along with recommended solutions:

• Cross-reactivity with related proteins: Polyclonal anti-SPAC1A6.10 antibodies may recognize similar epitopes in related proteins, especially other dehydratases. To mitigate this:

  • Pre-absorb antibodies with extracts from SPAC1A6.10 knockout cells

  • Use higher dilutions of primary antibody (1:2000-1:5000)

  • Include competitive blocking with recombinant protein

• Insufficient blocking: Inadequate blocking leads to high background. Improve blocking by:

  • Increasing blocking time to 2-3 hours

  • Using alternative blocking agents (5% BSA, commercial blocking buffers)

  • Adding 0.1-0.5% Triton X-100 or NP-40 to reduce hydrophobic interactions

• Sample contamination: Contaminants can create artifacts. Address by:

  • Implementing additional purification steps for protein extracts

  • Using fresh samples and reagents

  • Including appropriate controls (no primary antibody, isotype controls)

• Detection system issues: Over-development of signal can increase background. Optimize by:

  • Reducing substrate incubation time

  • Diluting detection reagents further

  • Using alternative detection systems with lower background

Systematic optimization of these parameters will help achieve optimal signal-to-noise ratio in experimental applications.

How should researchers prepare S. pombe samples for optimal SPAC1A6.10 detection?

Proper sample preparation is crucial for successful detection of SPAC1A6.10 in S. pombe cells:

• Cell growth conditions: Harvest cells during mid-logarithmic phase (OD600 0.5-0.8) when protein expression is typically optimal. Different growth media or stress conditions may affect SPAC1A6.10 expression levels.

• Cell lysis protocol:

  • Mechanical disruption with glass beads in a bead beater (8 cycles of 30 seconds on/30 seconds off on ice)

  • Use lysis buffer containing: 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM EDTA, 10% glycerol, 1 mM DTT

  • Add protease inhibitor cocktail immediately before use

  • Include phosphatase inhibitors if studying post-translational modifications

• Protein extraction optimization:

  • For membrane-associated fraction: include 1% NP-40 or 0.5% Triton X-100

  • For nuclear proteins: add nuclear extraction steps with 0.1% SDS

  • Clarify lysate by centrifugation at 14,000g for 15 minutes at 4°C

• Sample storage: Aliquot samples to avoid freeze-thaw cycles and store at -80°C with protease inhibitors. Use within 1-2 months for optimal results.

These methodological considerations ensure preservation of protein structure and epitope integrity for antibody recognition.

What control samples should be included when using SPAC1A6.10 antibodies in immunological assays?

Rigorous experimental design requires appropriate controls to validate findings and troubleshoot technical issues:

Essential controls for SPAC1A6.10 antibody experiments:

• Negative controls:

  • No primary antibody control (secondary antibody only)

  • Isotype control (non-specific IgG from same species as primary antibody)

  • Knockout/knockdown cell extracts (ΔSPAC1A6.10 strain)

  • Pre-immune serum control (for polyclonal antibodies)

• Positive controls:

  • Purified recombinant SPAC1A6.10 protein (≥85% purity)

  • Overexpression system (cells transformed with SPAC1A6.10 expression vector)

  • Previously validated positive samples

• Specificity controls:

  • Peptide competition assay (pre-incubation of antibody with immunizing peptide)

  • Cross-species samples (testing with related yeast species)

• Quantitative controls:

  • Loading control (anti-tubulin or anti-actin antibodies)

  • Standard curve using purified SPAC1A6.10 at known concentrations

  • Dilution series of sample to demonstrate signal linearity

Inclusion of these controls allows for proper interpretation of results and identification of technical artifacts versus genuine biological findings.

How can SPAC1A6.10 antibodies be used to investigate protein-protein interactions in tRNA modification pathways?

Investigating protein-protein interactions involving SPAC1A6.10 can provide insights into tRNA modification pathways and regulatory networks. Advanced methodological approaches include:

• Co-immunoprecipitation (Co-IP): Use anti-SPAC1A6.10 antibodies to pull down protein complexes from S. pombe lysates, followed by identification of interacting partners via Western blot or mass spectrometry. This approach requires:

  • Cross-linking optimization (0.1-1% formaldehyde for 10 minutes)

  • Gentle lysis conditions to preserve protein complexes

  • Use of magnetic beads conjugated with antibodies for efficient capture

  • Stringent washing conditions to remove non-specific binders

• Proximity-based labeling: Combine SPAC1A6.10 antibodies with proximity labeling approaches:

  • BioID fusion to SPAC1A6.10 followed by streptavidin pull-down

  • APEX2-mediated biotinylation of proximal proteins

  • Validation of interactions using reciprocal IP with antibodies against candidate interactors

• Förster Resonance Energy Transfer (FRET): Use fluorescently labeled antibodies to detect protein interactions:

  • Label anti-SPAC1A6.10 with donor fluorophore

  • Label antibodies against potential interacting proteins with acceptor fluorophore

  • Measure FRET signal in fixed cells or in vitro

• Chromatin Immunoprecipitation (ChIP): If SPAC1A6.10 associates with chromatin during tRNA processing:

  • Use anti-SPAC1A6.10 antibodies to identify genomic regions associated with the protein

  • Follow with DNA sequencing to map binding sites

  • Correlate with tRNA gene locations to establish functional connections

These approaches collectively provide a comprehensive view of the protein interaction network of SPAC1A6.10 in tRNA modification pathways.

What are the optimal immunofluorescence protocols for studying SPAC1A6.10 localization in S. pombe cells?

For subcellular localization studies of SPAC1A6.10 using immunofluorescence, researchers should implement this optimized protocol:

• Cell preparation:

  • Grow S. pombe cells to mid-log phase (OD600 = 0.5-0.7)

  • Fix with 3.7% formaldehyde for 30 minutes at room temperature

  • Wash 3× with PEM buffer (100 mM PIPES pH 6.9, 1 mM EGTA, 1 mM MgSO4)

  • Digest cell wall with Zymolyase (1 mg/ml) for 30-60 minutes at 37°C

  • Permeabilize with 1% Triton X-100 for 5 minutes

• Immunostaining procedure:

  • Block with 5% BSA in PEMBAL buffer for 1 hour

  • Incubate with anti-SPAC1A6.10 primary antibody (1:200 dilution) overnight at 4°C

  • Wash 3× with PEMBAL

  • Incubate with fluorophore-conjugated anti-rabbit secondary antibody (1:500) for 2 hours in the dark

  • Include DAPI (1 μg/ml) for nuclear counterstaining

  • Mount in anti-fade mounting medium

• Image acquisition settings:

  • Confocal microscopy with 63× or 100× oil immersion objective

  • Capture Z-stacks (0.3-0.5 μm steps) for 3D reconstruction

  • Use appropriate filter sets for secondary antibody fluorophore and DAPI

  • Maintain consistent exposure settings across samples

• Colocalization studies:

  • Co-stain with markers for cellular compartments:

    • Anti-histone for nucleus

    • Anti-SEC61 for endoplasmic reticulum

    • Anti-PMA1 for plasma membrane

    • Anti-COX4 for mitochondria

  • Calculate colocalization coefficients (Pearson's, Mander's)

These methodological details ensure reliable visualization of SPAC1A6.10's subcellular distribution and potential dynamic relocalization under different conditions.

How can researchers use anti-SPAC1A6.10 antibodies for quantitative analyses of protein expression levels across different experimental conditions?

Quantitative analysis of SPAC1A6.10 expression under various experimental conditions requires rigorous methodological approaches:

Table 2: Quantitative Methods for SPAC1A6.10 Expression Analysis

For all quantitative approaches, researchers should follow these critical considerations:

• Standardization: Include recombinant SPAC1A6.10 protein at known concentrations (85% purity or higher) as standard curve

• Replication: Perform at least 3-4 biological replicates and 2-3 technical replicates

• Statistical analysis: Apply appropriate statistical tests (ANOVA, t-test) with multiple testing correction

• Normalization: Use stable reference proteins (e.g., actin, GAPDH) for relative quantification

• Dynamic range assessment: Validate linearity of detection across expected concentration range

These methodological considerations ensure reliable quantification of SPAC1A6.10 expression changes in response to experimental variables.

How can researchers interpret contradictory results from different antibody-based detection methods for SPAC1A6.10?

When faced with contradictory results from different antibody-based methods, researchers should implement a systematic troubleshooting approach:

• Antibody validation reassessment:

  • Verify antibody specificity through knockout controls and peptide competition

  • Test multiple lots/sources of antibodies

  • Determine if epitope accessibility differs between methods

• Method-specific considerations:

  • Western blot: Protein denaturation may alter epitope recognition compared to native conditions

  • ELISA: Surface binding may detect only a subset of conformations

  • Immunofluorescence: Fixation protocols can mask epitopes

  • Immunoprecipitation: Buffer conditions may disrupt protein-antibody interactions

• Protein state factors:

  • Post-translational modifications may affect antibody recognition

  • Protein-protein interactions could mask epitopes in certain contexts

  • Conformational states may differ between experimental conditions

• Resolution approach:

  • Use orthogonal, non-antibody methods (mass spectrometry, RNA analysis)

  • Implement epitope tagging for alternative detection

  • Perform domain-specific analyses with multiple antibodies

  • Develop comprehensive validation using the PLAbDab database methodology for antibody characterization

Resolving contradictory results requires balancing technical limitations against biological reality to determine which findings most accurately reflect SPAC1A6.10 biology.

What are the implications of SPAC1A6.10's role in tRNA modification for broader cellular processes in S. pombe?

SPAC1A6.10's function as a tRNA threonylcarbamoyladenosine dehydratase (t(6)A37 dehydratase) has far-reaching implications for cellular processes:

• Translational accuracy:

  • t(6)A37 modification enhances codon-anticodon interactions

  • Defects in modification lead to increased translational errors

  • Impact on proteome integrity and protein folding quality control

• Stress response pathways:

  • tRNA modifications often respond to environmental stressors

  • SPAC1A6.10 activity may be regulated during cellular stress

  • Potential connection to stress-responsive gene expression programs

• Cell cycle regulation:

  • Precisely controlled translation is crucial for cell cycle progression

  • tRNA modification defects may lead to cell cycle checkpoints activation

  • SPAC1A6.10 could be differentially regulated across cell cycle phases

• Evolutionary conservation:

  • tRNA modification pathways are highly conserved across species

  • SPAC1A6.10 homologs likely perform similar functions in other organisms

  • Model for understanding fundamental aspects of tRNA biology

These broader implications suggest research directions where SPAC1A6.10 antibodies could be valuable tools for mechanistic investigations across multiple biological contexts.

How can SPAC1A6.10 antibodies contribute to understanding post-translational regulations of tRNA modification enzymes?

SPAC1A6.10 antibodies provide powerful tools for investigating post-translational regulation mechanisms:

• Modification-specific antibody applications:

  • Generate phospho-specific antibodies against predicted SPAC1A6.10 phosphorylation sites

  • Use anti-ubiquitin co-immunoprecipitation to detect ubiquitination status

  • Employ specialized antibodies for other modifications (acetylation, methylation, SUMOylation)

• Quantitative dynamics analysis:

  • Monitor SPAC1A6.10 levels throughout cell cycle using synchronized cultures

  • Quantify changes in protein abundance under various stress conditions

  • Measure protein half-life through cycloheximide chase experiments

• Regulatory complex investigation:

  • Use antibodies to purify native SPAC1A6.10 complexes under different conditions

  • Identify condition-specific interacting proteins by mass spectrometry

  • Map interaction domains through deletion mutant analysis

• In vivo activity correlation:

  • Correlate post-translational modification status with enzymatic activity

  • Measure t(6)A37 levels in tRNAs using specialized mass spectrometry

  • Develop in vitro activity assays using immunopurified SPAC1A6.10

These approaches collectively enable researchers to build comprehensive models of how SPAC1A6.10 activity is regulated post-translationally, connecting cellular signaling networks to tRNA modification outcomes.